tiprankstipranks
Trending News
More News >
Dr. Reddy's Laboratories Ltd (RDY)
NYSE:RDY
Advertisement

Dr Reddy's Laboratories (RDY) AI Stock Analysis

Compare
440 Followers

Top Page

RDY

Dr Reddy's Laboratories

(NYSE:RDY)

Select Model
Select Model
Select Model
Outperform 74 (OpenAI - 4o)
Rating:74Outperform
Price Target:
$16.00
▲(14.53% Upside)
Dr Reddy's Laboratories exhibits strong financial health with consistent growth in revenue and profitability, underpinned by a solid balance sheet. Technical analysis shows mixed signals, with potential for upward movement. Valuation is fair, and the earnings call highlights both growth opportunities and challenges. Regulatory observations and market softness in the U.S. generics segment are notable risks.

Dr Reddy's Laboratories (RDY) vs. SPDR S&P 500 ETF (SPY)

Dr Reddy's Laboratories Business Overview & Revenue Model

Company DescriptionDr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
How the Company Makes MoneyDr. Reddy's Laboratories generates revenue primarily through the sale of generic pharmaceuticals, which include both branded and unbranded versions of established drugs. The company also earns significant income from the production and sale of active pharmaceutical ingredients (APIs) to other pharmaceutical companies. Additional revenue streams include contributions from its proprietary brands and over-the-counter (OTC) products. The company has established partnerships with various organizations for research and development, co-marketing arrangements, and distribution, which enhance its market reach and profitability. Factors contributing to its earnings include the company's ability to successfully navigate regulatory approvals, efficient production processes, and strategic expansions into new markets and therapeutic areas.

Dr Reddy's Laboratories Earnings Call Summary

Earnings Call Date:Jul 29, 2025
(Q1-2026)
|
% Change Since: |
Next Earnings Date:Oct 24, 2025
Earnings Call Sentiment Neutral
The earnings call presented a mixed performance with solid revenue growth in several segments and strategic advancements in biosimilars and environmental achievements. However, challenges remain with declines in the U.S. generics market and a decrease in gross profit margins, along with regulatory observations from the USFDA.
Q1-2026 Updates
Positive Updates
Double-Digit Revenue Growth
Revenue grew by 11% year-over-year, driven by broad-based performance across most markets, except the U.S. generics business.
Biosimilar Business Momentum
Gained momentum through strategic collaboration with Alvotech for pembrolizumab, a biosimilar Keytruda, and sustained commitment to biosimilar development.
Environmental Leadership
Dr. Reddy's Carbon Disclosure Project (CDP) rating was elevated to an A, placing it among the top 2% globally.
India Business Growth
India business delivered a double-digit year-on-year growth of 11% with a 13% sequential increase, driven by new products and pricing.
Negative Updates
US Generics Revenue Decline
North American business revenue declined by 17% year-on-year and 4% sequentially, primarily due to price erosion in selected products.
Gross Profit Margin Decline
Consolidated gross profit margin decreased by 350 basis points year-on-year, attributed to price erosion and lower operating leverage.
Observations from USFDA Inspections
USFDA issued Form 483 observations for multiple facilities, including Middleburg API facility and CTO-5 API facility, requiring responses.
Company Guidance
During Dr. Reddy's Laboratories' Q1 FY '26 earnings call, the company reported a steady double-digit revenue growth of 11% year-over-year, translating to INR 8,545 crores (USD 997 million). The EBITDA margin stood at 26.7%, slightly surpassing their target of 25%. However, the gross profit margin decreased by 350 basis points year-over-year to 56.9%, mainly due to price erosion in the generic segment, particularly lenalidomide. The SG&A expenses rose 13% year-over-year to INR 2,565 crores (USD 299 million), driven by strategic investments in consumer health care and nutraceuticals. R&D spend was INR 624 crores (USD 73 million), accounting for 7.3% of sales. The company maintained a net cash surplus of INR 2,922 crores (USD 341 million) and hedged USD 648 million using derivative contracts. The effective tax rate for the quarter was 25.9%, with the profit after tax reaching INR 1,419 crores (USD 166 million). Looking ahead, Dr. Reddy's anticipates growth driven by new product launches and strategic investments, although the U.S. generics market showed some softness.

Dr Reddy's Laboratories Financial Statement Overview

Summary
Dr Reddy's Laboratories demonstrates strong financial performance with consistent revenue and profit growth. The company achieved a Gross Profit Margin of 58.5% and a Net Profit Margin of 17.4% for the fiscal year ending March 2025. Revenue growth rate from 2024 to 2025 was 16.6%, indicating a robust growth trajectory. The balance sheet reflects a solid financial position with a strong equity base and low financial leverage. Cash flow remains healthy despite a slight decline, supporting operational and investment needs.
Income Statement
85
Very Positive
Dr Reddy's Laboratories demonstrates strong financial performance with consistent revenue and profit growth. The company achieved a Gross Profit Margin of 58.5% and a Net Profit Margin of 17.4% for the fiscal year ending March 2025. Revenue growth rate from 2024 to 2025 was 16.6%, indicating a robust growth trajectory. EBIT Margin and EBITDA Margin were 22.1% and 29.7%, respectively, showcasing efficient cost management and operational profitability.
Balance Sheet
82
Very Positive
The balance sheet of Dr Reddy's Laboratories reflects a solid financial position with a strong equity base. The Debt-to-Equity Ratio stands at a manageable 0.14, indicating low financial leverage. Return on Equity (ROE) is impressive at 16.96% for the year ending March 2025, suggesting effective utilization of equity to generate profits. The Equity Ratio is 67.6%, highlighting a strong capital structure with a significant portion of assets financed by equity.
Cash Flow
78
Positive
Dr Reddy's Laboratories portrays a stable cash flow position with a Free Cash Flow to Net Income Ratio of 0.21 for the fiscal year ending March 2025. The Operating Cash Flow to Net Income Ratio is 0.82, indicating robust cash generation capabilities relative to net income. Despite a decrease in Free Cash Flow from the previous year, the company's cash flow remains healthy and supports its operational and investment needs.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue325.54B325.54B279.16B245.88B214.39B189.72B
Gross Profit190.43B190.43B163.61B202.97B113.84B103.08B
EBITDA95.20B96.67B88.42B74.43B47.74B45.71B
Net Income56.54B56.54B55.68B45.07B23.57B17.24B
Balance Sheet
Total Assets492.99B492.99B387.52B322.85B296.65B265.49B
Cash, Cash Equivalents and Short-Term Investments57.91B57.91B81.47B66.75B44.37B34.57B
Total Debt46.77B46.77B20.02B13.47B33.84B30.31B
Total Liabilities155.82B155.82B106.97B89.99B106.13B90.51B
Stockholders Equity333.39B333.39B280.55B232.86B190.53B174.98B
Cash Flow
Free Cash Flow12.03B12.03B18.00B40.01B9.06B23.14B
Operating Cash Flow46.43B46.43B45.43B58.87B28.11B35.70B
Investing Cash Flow-58.08B-58.08B-40.28B-41.37B-26.39B-22.66B
Financing Cash Flow18.91B18.91B-3.76B-26.86B-2.42B-298.00M

Dr Reddy's Laboratories Technical Analysis

Technical Analysis Sentiment
Negative
Last Price13.97
Price Trends
50DMA
14.30
Negative
100DMA
14.53
Negative
200DMA
14.18
Negative
Market Momentum
MACD
-0.02
Positive
RSI
36.51
Neutral
STOCH
8.42
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RDY, the sentiment is Negative. The current price of 13.97 is below the 20-day moving average (MA) of 14.47, below the 50-day MA of 14.30, and below the 200-day MA of 14.18, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 36.51 is Neutral, neither overbought nor oversold. The STOCH value of 8.42 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RDY.

Dr Reddy's Laboratories Risk Analysis

Dr Reddy's Laboratories disclosed 60 risk factors in its most recent earnings report. Dr Reddy's Laboratories reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Dr Reddy's Laboratories Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
78
Outperform
$14.08B41.9112.93%18.42%1.47%
74
Outperform
$11.79B17.7817.48%0.64%13.13%-0.47%
66
Neutral
$3.06B1,523.44-3.00%9.81%
58
Neutral
$21.65B-126.83-30.46%2.43%64.37%
54
Neutral
$11.10B-3.27-3.40%5.04%-7.47%-438.39%
51
Neutral
$2.95B-38.39-1.80%5.34%-2.32%35.46%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
RDY
Dr Reddy's Laboratories
13.97
-1.84
-11.64%
VTRS
Viatris
9.62
-1.46
-13.18%
NBIX
Neurocrine
140.27
25.05
21.74%
PRGO
Perrigo Company
21.73
-3.40
-13.53%
TEVA
Teva Pharmaceutical
19.18
1.16
6.44%
AMRX
Amneal Pharmaceuticals
9.87
1.55
18.63%

Dr Reddy's Laboratories Corporate Events

Dr. Reddy’s Receives Positive CHMP Opinion for AVT03 Biosimilar
Sep 22, 2025

On September 22, 2025, Dr. Reddy’s Laboratories announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization for AVT03, a biosimilar of Prolia® and Xgeva®, in European markets. This development is a significant step for Dr. Reddy’s as it strengthens their position in the biosimilars market, potentially expanding their reach in Europe and the UK, and offering new treatment options under the tradenames Acvybra® and Xbonzy® upon approval.

Dr. Reddy’s Laboratories Schedules Board Meeting for Financial Results Review
Sep 22, 2025

Dr. Reddy’s Laboratories has announced a Board meeting scheduled for October 24, 2025, to review and approve the company’s unaudited financial results for the quarter ending September 30, 2025. In compliance with SEBI regulations, the company will close its trading window from September 24 to October 26, 2025, to prevent insider trading. This announcement is significant for stakeholders as it outlines the company’s commitment to transparency and regulatory compliance, which may impact investor confidence and market performance.

Dr. Reddy’s Promoters Transfer Shares to Family Trusts for Succession Planning
Sep 19, 2025

On September 17, 2025, Dr. Reddy’s Laboratories announced the transfer of 20.58% of its equity shares by its promoters to private family trusts. This move, involving the transfer of shares by Satish Reddy Kallam and G V Prasad to the VSD Family Trust and GVP Family Trust respectively, is part of a succession planning strategy. The transfer, which was facilitated by an exemption from SEBI, does not alter the management or control of the company, ensuring stability for stakeholders.

Dr. Reddy’s Launches Tegoprazan in India for Gastrointestinal Diseases
Sep 16, 2025

On September 16, 2025, Dr. Reddy’s Laboratories announced the launch of Tegoprazan, a novel potassium-competitive acid blocker, in India under the brand name PCAB®. This launch follows their 2022 partnership with South Korea’s HK inno.N Corporation to commercialize Tegoprazan in India and select emerging markets. Tegoprazan is designed to treat acid-related gastrointestinal diseases such as GERD and gastric ulcers, offering a fast onset of action and prolonged gastric pH control. With acid peptic diseases affecting approximately 38% of the Indian population, this launch aims to fill a critical gap in treatment options, potentially improving patient outcomes. Tegoprazan has already been approved in 21 countries and is undergoing registration in several others, including successful completion of a Phase-III trial in the United States.

Dr. Reddy’s Laboratories Allots Equity Shares Under Employee Stock Option Scheme
Sep 15, 2025

On September 15, 2025, Dr. Reddy’s Laboratories announced the allotment of 6,475 equity shares to eligible employees as part of its Employees ADR Stock Options Scheme, 2007. This move reflects the company’s ongoing commitment to employee engagement and retention through stock-based incentives. The newly issued shares are fully paid up and rank pari passu with existing shares, contributing to the company’s total issued share capital of Rs. 83,46,14,760. This strategic allocation is expected to enhance employee motivation and align their interests with the company’s growth objectives.

Dr. Reddy’s Laboratories Receives USFDA Observations Post-Inspection
Sep 15, 2025

On September 12, 2025, Dr. Reddy’s Laboratories announced that the USFDA completed a Pre-Approval Inspection at their biologics manufacturing facility in Bachupally, Hyderabad. The inspection, which took place from September 4 to September 12, 2025, resulted in a Form 483 with five observations. The company has committed to addressing these observations within the stipulated timeline, which is crucial for maintaining compliance and advancing their market position in the biologics sector.

Dr. Reddy’s Acquires STUGERON® Portfolio to Enhance CNS Offerings
Sep 11, 2025

On September 10, 2025, Dr. Reddy’s Laboratories announced the acquisition of the STUGERON® brand from Janssen Pharmaceutica NV, an affiliate of Johnson & Johnson. This acquisition, valued at USD 50.5 million, includes the STUGERON® portfolio across 18 markets in the APAC and EMEA regions, with India and Vietnam as key markets. The acquisition strengthens Dr. Reddy’s Central Nervous System (CNS) portfolio by expanding into the anti-vertigo segment, leveraging STUGERON®’s leading position in the Cinnarizine market in India. This strategic move aligns with Dr. Reddy’s broader goal of enhancing patient access and aims to reach over 1.5 billion patients by 2030.

Dr. Reddy’s Laboratories Receives USFDA Observations at UK Facility
Sep 8, 2025

Dr. Reddy’s Laboratories recently underwent a GMP inspection by the USFDA at its API Mirfield facility in West Yorkshire, UK, from September 1 to September 5, 2025. The inspection resulted in a Form 483 with seven observations, which the company intends to address within the stipulated timeline, potentially impacting its compliance and operational standards.

Dr. Reddy’s Faces Customs Penalty for Export Incentives
Sep 4, 2025

On September 3, 2025, Dr. Reddy’s Laboratories received an order from the Joint Commissioner of Customs in Ludhiana, Punjab, imposing a penalty under the Customs Act, 1962, for allegedly availing export incentives irregularly. The penalty amounts to Rs. 3,00,00,000, but the company has assessed that this will not materially impact its financials, operations, or other activities. Dr. Reddy’s is considering filing an appeal against this order.

Dr. Reddy’s Laboratories to Participate in Investor Conference on September 5, 2025
Sep 2, 2025

On September 2, 2025, Dr. Reddy’s Laboratories announced its participation in an upcoming investor conference organized by Investec, scheduled for September 5, 2025. The meeting will be conducted virtually and will involve group discussions with institutional investors, reflecting the company’s ongoing engagement with its stakeholders and efforts to maintain transparency in its operations.

Dr. Reddy’s Laboratories Announces Resignation of CHRO
Sep 2, 2025

Dr. Reddy’s Laboratories announced that Ms. Archana Bhaskar has resigned from her role as Chief Human Resources Officer (CHRO), effective November 30, 2025. This change in senior managerial personnel is part of the company’s ongoing adjustments and may impact its human resources strategy and operations.

Dr. Reddy’s Laboratories Allots Equity Shares to Employees
Aug 29, 2025

On August 29, 2025, Dr. Reddy’s Laboratories announced the allotment of 21,350 equity shares to eligible employees under its stock options schemes. This move is part of the company’s ongoing efforts to incentivize and retain talent through its Employees Stock Options Scheme, 2002, and Employees ADR Stock Options Scheme, 2007. The issuance of these shares reflects the company’s commitment to employee engagement and aligns with its strategic objectives of enhancing shareholder value.

Dr. Reddy’s Laboratories Secures Interim Stay on Tax Reassessment Order
Aug 26, 2025

On August 26, 2025, Dr. Reddy’s Laboratories announced that the Telangana High Court has granted an interim stay on a reassessment order issued by the Income Tax Authority concerning alleged tax escapement following the merger of Dr. Reddy’s Holding Limited into Dr. Reddy’s Laboratories Limited. The company had previously received a show cause notice and an order for reassessment, prompting it to file a writ petition seeking to quash the proceedings. Dr. Reddy’s maintains that there has been no tax escapement and is monitoring the situation closely, with assurances that the company’s promoters will indemnify the company against any liabilities arising from the merger.

Dr. Reddy’s Laboratories Allots Equity Shares Under ESOP
Aug 21, 2025

On August 20, 2025, Dr. Reddy’s Laboratories announced the allotment of 4,160 equity shares to eligible employees under its Employees Stock Options Scheme, 2002. This move is part of the company’s ongoing efforts to incentivize and retain talent, potentially enhancing employee satisfaction and aligning their interests with the company’s growth objectives.

Dr. Reddy’s Laboratories to Engage in Virtual Investor Conference on August 21, 2025
Aug 13, 2025

On August 13, 2025, Dr. Reddy’s Laboratories announced its participation in an upcoming investor conference organized by Centrum Broking, scheduled for August 21, 2025. The meeting will be conducted virtually and will involve group discussions with institutional investors. This engagement reflects Dr. Reddy’s commitment to maintaining transparency and communication with its stakeholders, potentially impacting investor relations and market perception.

Dr. Reddy’s Laboratories Receives Positive USFDA Inspection Outcome
Aug 11, 2025

On August 7, 2025, Dr. Reddy’s Laboratories received an Establishment Inspection Report (EIR) from the United States Food & Drug Administration (USFDA) for its API manufacturing facility in Miryalaguda, Telangana, India. The inspection, which was initially conducted in May 2025, was classified as ‘Voluntary Action Indicated (VAI)’, indicating that the inspection is officially closed. This outcome suggests that while there were some issues noted, they are not significant enough to warrant further regulatory action, which is a positive development for the company’s compliance status and operational stability.

Dr. Reddy’s Subsidiary Imperial Dissolved Following NCLT Approval
Aug 8, 2025

On August 5, 2025, the National Company Law Tribunal in Hyderabad approved the voluntary liquidation of Dr. Reddy’s Laboratories’ wholly-owned subsidiary, Imperial Owners and Land Possessions Private Limited. The dissolution of Imperial, which is not a material subsidiary, will not significantly impact Dr. Reddy’s consolidated financials.

Dr. Reddy’s Laboratories Concludes 41st AGM with Key Resolutions
Jul 25, 2025

On July 24, 2025, Dr. Reddy’s Laboratories held its 41st Annual General Meeting (AGM) via video conferencing, where key business and financial matters were discussed. The meeting included the adoption of the company’s audited financial statements for the year ending March 31, 2025, and the declaration of a dividend of Rs. 8 per equity share. Additionally, the re-appointment of Mr. G V Prasad as a director and Co-Chairman and Managing Director was approved. The AGM also covered special business items such as the approval of remuneration for cost auditors and the appointment of a new secretarial auditor. The meeting facilitated electronic voting for members to ensure a transparent decision-making process.

Dr. Reddy’s Laboratories Releases Q1 2025 Financial Results
Jul 25, 2025

On July 24, 2025, Dr. Reddy’s Laboratories announced the publication of its unaudited financial results for the quarter ending June 30, 2025. The results were advertised in the Financial Express and Andhra Prabha newspapers, highlighting the company’s ongoing transparency and compliance with regulatory requirements. This announcement underscores Dr. Reddy’s commitment to maintaining investor confidence and adhering to financial disclosure norms.

Dr. Reddy’s Re-appoints G V Prasad as Co-Chairman and Managing Director
Jul 24, 2025

On July 24, 2025, Dr. Reddy’s Laboratories announced the re-appointment of Mr. G V Prasad as Co-Chairman and Managing Director for a five-year term starting January 30, 2026. This decision, approved by the shareholders at the company’s 41st AGM, underscores the company’s commitment to leadership continuity and strategic growth, leveraging Mr. Prasad’s extensive experience in the pharmaceutical industry.

Dr. Reddy’s Laboratories Appoints New Secretarial Auditors
Jul 24, 2025

On July 24, 2025, Dr. Reddy’s Laboratories announced that its shareholders approved the appointment of Makarand M. Joshi & Co. as the Secretarial Auditors for a five-year term starting April 1, 2025. This decision, made during the company’s 41st Annual General Meeting, underscores Dr. Reddy’s commitment to maintaining robust corporate governance practices, potentially enhancing its credibility and operational transparency in the pharmaceutical industry.

Dr. Reddy’s Laboratories Releases Q1 2025 Earnings Call Audio
Jul 24, 2025

On July 23, 2025, Dr. Reddy’s Laboratories announced the availability of audio recordings from their earnings call for the quarter ending June 30, 2025. The announcement is part of their regulatory compliance under the Securities and Exchange Board of India regulations, indicating transparency and communication with stakeholders. This move is likely to impact stakeholders by providing insights into the company’s financial performance and strategic direction.

Dr. Reddy’s Laboratories to Appoint Deloitte as Statutory Auditors from FY 2026-27
Jul 23, 2025

On July 23, 2025, Dr. Reddy’s Laboratories announced its intention to appoint Deloitte Haskins & Sells LLP as its Statutory Auditors for five years starting from FY 2026-27. This decision, pending regulatory approval, marks a strategic move as the company transitions from its current auditors, M/s. S.R. Batliboi & Associates LLP, whose term concludes at the 42nd AGM in 2026. The appointment reflects Dr. Reddy’s commitment to maintaining high standards of audit independence and compliance, potentially impacting its operational transparency and stakeholder confidence.

Dr. Reddy’s Laboratories Releases Q1 FY26 Financial Results
Jul 23, 2025

On July 23, 2025, Dr. Reddy’s Laboratories announced the presentation of its unaudited financial results for the first quarter of the fiscal year 2026, which ended on June 30, 2025. This announcement is part of the company’s compliance with the Securities and Exchange Board of India’s regulations and aims to keep stakeholders informed about its financial performance. The release of these results could impact the company’s market positioning and provide insights into its operational strategies.

Dr. Reddy’s Laboratories Quarterly Report Highlights Stability as of June 2025
Jul 23, 2025

Dr. Reddy’s Laboratories released its quarterly report for the period ending June 30, 2025, detailing its financial performance and operations. The report, reviewed by Ernst & Young Associates LLP, indicates no material modifications required for compliance with International Accounting Standards. This quarterly review highlights the company’s stable financial position and adherence to regulatory standards, which could positively impact its market reputation and stakeholder confidence.

Dr. Reddy’s Laboratories Reports Q1 FY2026 Financial Results
Jul 23, 2025

On July 23, 2025, Dr. Reddy’s Laboratories announced its financial results for the quarter ending June 30, 2025. The company released unaudited consolidated and standalone financial results in accordance with both International Financial Reporting Standards (IFRS) and Indian Accounting Standards (Ind AS). This disclosure, following a board meeting, highlights the company’s commitment to transparency and regulatory compliance, potentially impacting its market positioning and stakeholder confidence.

Dr. Reddy’s Laboratories Opens Special Window for Share Transfer Requests
Jul 22, 2025

On July 22, 2025, Dr. Reddy’s Laboratories announced the publication of a newspaper advertisement regarding the opening of a special window for the re-lodgment of transfer requests for physical shares. This initiative, published in Business Standard and Nava Telangana, is in compliance with SEBI’s regulations and aims to facilitate the transfer process for stakeholders, reflecting the company’s commitment to regulatory adherence and shareholder engagement.

Dr. Reddy’s API Facility Passes USFDA Inspection with VAI Classification
Jul 21, 2025

On July 21, 2025, Dr. Reddy’s Laboratories announced that the United States Food & Drug Administration (USFDA) has completed its inspection of the company’s API facility in Middleburgh, New York. The inspection, which took place earlier in the year, resulted in a classification of ‘Voluntary Action Indicated (VAI)’ and is now officially closed. This outcome indicates that while some issues were noted, they do not require immediate corrective action and the facility continues to operate within acceptable standards. This development is significant for Dr. Reddy’s as it reinforces the company’s compliance with US regulatory standards, potentially strengthening its market position in the United States.

USFDA Completes Inspection at Dr. Reddy’s Facility with Observations
Jul 18, 2025

On July 18, 2025, Dr. Reddy’s Laboratories announced that the USFDA completed a GMP and Pre-Approval Inspection at its FTO 11 formulations manufacturing facility in Srikakulam, Andhra Pradesh. The inspection, conducted from July 10 to July 18, resulted in a Form 483 with seven observations, which the company plans to address within the stipulated timeline. This inspection is crucial for the company’s compliance and operational standards, potentially impacting its market positioning and stakeholder confidence.

Dr. Reddy’s Laboratories to Announce Q1FY26 Results on July 23, 2025
Jul 15, 2025

On July 15, 2025, Dr. Reddy’s Laboratories announced that it will release its Q1FY26 financial results on July 23, 2025, following a Board Meeting. An earnings call is scheduled for the same day at 19:30 PM IST / 10:00 AM ET to discuss the company’s financial performance. The results will be made available through stock exchanges, media, the company’s website, and email, with a press meet presentation and earnings call transcript also accessible online. This announcement is significant as it provides stakeholders with insights into the company’s financial health and strategic direction for the upcoming fiscal year.

Dr. Reddy’s Laboratories Announces 41st AGM Notice and E-Voting Information
Jul 2, 2025

On July 2, 2025, Dr. Reddy’s Laboratories announced the publication of a newspaper advertisement regarding the notice of its 41st Annual General Meeting and e-voting information. This announcement, made in compliance with Regulation 47 of the Securities and Exchange Board of India, was published in the Business Standard and Nava Telangana newspapers. The move underscores the company’s commitment to transparency and regulatory compliance, ensuring stakeholders are informed about important corporate governance events.

Dr. Reddy’s Laboratories Releases 2024-25 Integrated Annual Report
Jul 1, 2025

On June 30, 2025, Dr. Reddy’s Laboratories announced the release of its Integrated Annual Report for the financial year 2024-25. The report has been made available electronically to shareholders who have registered their email addresses, and a web link has been provided for those who have not. This move reflects the company’s commitment to transparency and regulatory compliance, potentially strengthening its relationship with stakeholders and enhancing its market position.

Dr. Reddy’s Laboratories Releases FY2025 Sustainability Report
Jun 30, 2025

On June 30, 2025, Dr. Reddy’s Laboratories released its Business Responsibility and Sustainability Report (BRSR) for the financial year 2024-25. This report, which is part of the company’s Integrated Annual Report, highlights the company’s commitment to sustainability and responsible business practices. The BRSR is available on the company’s website, indicating Dr. Reddy’s ongoing efforts to maintain transparency and accountability in its operations, which is crucial for its stakeholders and industry positioning.

Dr. Reddy’s Laboratories Schedules 41st AGM for July 2025
Jun 30, 2025

Dr. Reddy’s Laboratories announced the scheduling of its 41st Annual General Meeting (AGM) on July 24, 2025, at 11:00 A.M. IST, which will be conducted through video conferencing. The announcement includes details about the e-voting process, which will be available from July 20 to July 23, 2025, providing shareholders with the opportunity to participate and vote on company matters remotely.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 26, 2025